SCHEMBL2303671

SCHEMBL2303671

CCc1sc(NC(=O)c2ccc(Cl)nc2)nc1-c1ccccc1

nearest known ligand 0.58

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 7/20 0.58
RAB9A P51151 5/20 0.58
MAPT P10636 2/20 0.58
PKM P14618 1/20 0.58
HSD17B10 Q99714 2/20 0.56
HPGD P15428 1/20 0.56
TSHR P16473 1/20 0.56
PTGDR2 Q9Y5Y4 1/20 0.54
NPC1 O15118 3/20 0.53
POLB P06746 2/20 0.53
KMT2A Q03164 2/20 0.53
MEN1 O00255 1/20 0.53
LMNA P02545 2/20 0.50
ADORA3 P0DMS8 2/20 0.50
ADORA1 P30542 2/20 0.50
KDM4E B2RXH2 1/20 0.50
ADORA2A P29274 1/20 0.50
RORC P51449 1/20 0.50
SMN1; SMN2 Q16637 1/20 0.49
KCNQ3 O43525 1/20 0.48

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2302150 0.85 ALDH1A1 (0.68) ALDH1A1RAB9AMAPTPKMHSD17B10
SCHEMBL20416878 0.83 RAB9A (0.53) ALDH1A1RAB9AMAPTPKMPTGDR2
SCHEMBL2302641 0.83 MEN1 (0.66) ALDH1A1MAPTHPGDKMT2AMEN1
SCHEMBL20417255 0.80 ADORA3 (0.60) ALDH1A1RAB9AMAPTPKMNPC1
SCHEMBL16607136 0.80 ALDH1A1 (0.61) ALDH1A1RAB9AMAPTHSD17B10HPGD
SCHEMBL13256169 0.78 RAB9A (0.50) ALDH1A1RAB9AMAPTPKMNPC1
SCHEMBL14960379 0.77 ALDH1A1 (0.74) ALDH1A1RAB9AMAPTHSD17B10HPGD
SCHEMBL2300697 0.76 RAB9A (0.60) ALDH1A1RAB9AMAPTPKMHPGD
SCHEMBL2303467 0.76 RAB9A (0.59) ALDH1A1RAB9AMAPTPKMPTGDR2
SCHEMBL9892859 0.76 ALDH1A1 (0.81) ALDH1A1RAB9AMAPTHSD17B10HPGD

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2350311-B1 DIACYLGLYCEROL ACYLTRANSFERASE INHIBITORS MADRIGAL PHARMACEUTICALS INC (US) 2013-12-25 EP disclosed
US-8324385-B2 Diacylglycerol acyltransferase inhibitors MADRIGAL PHARMACEUTICALS, INC. (US) 2012-12-04 US disclosed
US-8324385-B2 Diacylglycerol acyltransferase inhibitors MADRIGAL PHARMACEUTICALS, INC. (US) 2012-12-04 US disclosed
CN-102203280-A Diacylglycerol acyltransferase inhibitors VIA PHARMACEUTICALS INC 2011-09-28 CN disclosed
EP-2350311-A1 DIACYLGLYCEROL ACYLTRANSFERASE INHIBITORS Via Pharmaceuticals, Inc. (US) 2011-08-03 EP disclosed
WO-2010056506-A1 DIACYLGLYCEROL ACLYTRANSFERASE INHIBITORS VIA PHARMACEUTICALS, INC. (US) 2010-05-20 WO disclosed
US-20100113782-A1 Diacylglycerol Acyltransferase Inhibitors MADRIGAL PHARMACEUTICALS, INC. 2010-05-06 US disclosed
US-20100113782-A1 Diacylglycerol Acyltransferase Inhibitors MADRIGAL PHARMACEUTICALS, INC. 2010-05-06 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100113782-A1 Diacylglycerol Acyltransferase Inhibitors DGAT2, DGAT1, MOGAT2 ALDH1A1 802/4885RAB9A 2586/4885MAPT 4008/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.